Previous close | 386.70 |
Open | N/A |
Bid | 315.00 |
Ask | 324.00 |
Strike | 1,300.00 |
Expiry date | 2024-11-15 |
Day's range | 386.70 - 386.70 |
Contract range | N/A |
Volume | |
Open interest | N/A |
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.